SCHEMBL6358201

SCHEMBL6358201

COC(=O)C(C)(C)NCC(=O)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.49
RAB9A P51151 4/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
HPGD P15428 3/20 0.49
ALDH1A1 P00352 3/20 0.49
AGTR1 P30556 2/20 0.49
SRC P12931 1/20 0.49
KMT2A Q03164 5/20 0.47
MEN1 O00255 4/20 0.47
MAPT P10636 2/20 0.47
KDM4E B2RXH2 2/20 0.47
CYP3A4 P08684 2/20 0.47
ALOX15 P16050 1/20 0.47
CES1 P23141 1/20 0.47
MAPK1 P28482 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
KCNN4 O15554 1/20 0.44
ELANE P08246 1/20 0.44
PTPN1 P18031 2/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15748713 0.84 KMT2A (0.52) NPC1RAB9ASMN1; SMN2HPGDALDH1A1
SCHEMBL10788888 0.80 KMT2A (0.56) NPC1RAB9ASMN1; SMN2HPGDALDH1A1
Hydrochloric Acid SCHEMBL28169360 0.79 KMT2A (0.54) NPC1RAB9ASMN1; SMN2HPGDALDH1A1
SCHEMBL1226527 0.78 SLC6A3 (0.40) NPC1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL380738 0.77 SRC (0.53) NPC1RAB9ASMN1; SMN2HPGDALDH1A1
SCHEMBL4400325 0.76 KMT2A (0.50) NPC1RAB9ASMN1; SMN2HPGDALDH1A1
SCHEMBL21328307 0.76 RIPK1 (0.47) NPC1RAB9ASMN1; SMN2HPGDALDH1A1
SCHEMBL27484083 0.73 KCNN4 (0.53) NPC1RAB9ASMN1; SMN2HPGDALDH1A1
SCHEMBL28309572 0.72 ALDH1A1 (0.47) NPC1RAB9ASMN1; SMN2HPGDALDH1A1
SCHEMBL29110133 0.72 SRC (0.56) NPC1RAB9ASMN1; SMN2HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6960575-B2 For use as inhibitors of chymase SANTEN PHARMACEUTICAL CO., LTD. (JP) 2005-11-01 US disclosed
US-20040097496-A1 Novel thiazine derivatives SANTEN PHARMACEUTICAL CO.,LTD. (JP) 2004-05-20 US disclosed
US-6713472-B1 2-OXO-1,2,3,4-TETRAHYDROPYRAZINE DERIVATIVES; CHYMASE INHIBITORS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-03-30 US disclosed
EP-1211249-A1 NOVEL THIAZINE OR PYRAZINE DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097496-A1 Novel thiazine derivatives CMA1, TPSD1, HRH4 NPC1 2985/4885RAB9A 3356/4885SMN1; SMN2 4138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.